Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
- PMID: 26705758
- PMCID: PMC4807395
- DOI: 10.1007/s11940-015-0387-9
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.
Keywords: Azathioprine; Eculizumab; Immunosuppression; Mycophenolate; Neuromyelitis optica spectrum disorder; Rituximab.
Conflict of interest statement
References
-
- Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–1180. - PubMed
-
- Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review. J Neurol Sci. 2015;355(1–2):7–17. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources